Product Information
ALOGLIPTIN-METFORMIN 12.5-500 is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $2.3006 per EA under NDC 45802016972. Its NADAC has been published 488 times since Apr 19, 2017.
FDA first approved this application on Jan 25, 2013.
Strength
12.5; 500 mg/1; mg/1
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802016972
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDEApproval Type
Authorized Generic (NDA)
FDA Application
NDA203414FDA Approved
1/25/2013
On Market Since
4/8/2016
Pharmacological Classes
Price Statistics
The NADAC for ALOGLIPTIN-METFORMIN 12.5-500 has been published 488 times since Apr 19, 2017, and over the history we have for it it has declined 23.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.3006 per EA |
|---|---|
| All-time high | $2.9989 (Sep 13, 2017) |
| All-time low | $1.9997 (Jan 17, 2024) |
| 52-week high | $2.3377 |
| 52-week low | $2.1610 |
| Median price | $2.4968 |
| Average price | $2.4731 |
| Largest weekly change | -19.9% (Jan 17, 2024) |
| Weeks tracked | 488 |
| Tracking since | Apr 19, 2017 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of ALOGLIPTIN-METFORMIN 12.5-500?
The current National Average Drug Acquisition Cost (NADAC) for ALOGLIPTIN-METFORMIN 12.5-500, manufactured by Padagis Israel Pharmaceuticals Ltd, is $2.3006 per EA (NDC 45802016972), effective Aug 19, 2026.
How has the price of ALOGLIPTIN-METFORMIN 12.5-500 changed over time?
Over the history we have for it, the NADAC for ALOGLIPTIN-METFORMIN 12.5-500 has declined 23.3%. It has been tracked across 488 weekly CMS publications since Apr 19, 2017.
What are the highest and lowest recorded NADAC prices for ALOGLIPTIN-METFORMIN 12.5-500?
Since Apr 19, 2017, the NADAC for ALOGLIPTIN-METFORMIN 12.5-500 has ranged from a low of $1.9997 (Jan 17, 2024) to a high of $2.9989 (Sep 13, 2017), with a median of $2.4968 per EA.
Are there cheaper alternatives to ALOGLIPTIN-METFORMIN 12.5-500?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as ALOGLIPTIN-METFORMIN 12.5-500 in a comparable dosage form, but none are currently priced below it.
Who manufactures ALOGLIPTIN-METFORMIN 12.5-500?
ALOGLIPTIN-METFORMIN 12.5-500 (NDC 45802016972) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.